A meta-analysis of individual patient data examined the use and duration of hormone therapy in combination with postoperative radiotherapy (PORT) in recurrent prostate cancer. The findings show that the addition of hormone therapy, either short-term or long-term, to PORT in patients with a PSA of 0.5 ng/mL or less has no significant overall survival benefit. No apparent difference in efficacy was found between short-term and long-term hormone therapy. These results provide the strongest level of evidence for this question. There is an unmet need to identify biomarkers to predict the potential benefit of hormone therapy.